Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T21503 |
(E/Z)-Zotiraciclib
(E/Z)-TG02,(E/Z)-SB1317 |
FLT; JAK; CDK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
(E/Z)-Zotiraciclib ((E/Z)-TG02) 是一种 CDK2、JAK2和FLT3的抑制剂,IC50分别为 13、73 和 56 nM。 | |||
T2653 |
SB1317
TG02 |
FLT; JAK; CDK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
SB1317 (TG02) 是一种有效的细胞周期蛋白依赖性激酶 (CDKs)、Janus 激酶 2 (JAK2) 和 Fms 样酪氨酸激酶-3 (FLT3) 抑制剂。 | |||
T4227 |
SB1317 hydrochloride (1204918-72-8(free base))
TG-02 hydrochloride,14-甲基-20-氧杂-5,7,14,27-四氮杂四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2,4,6(27),8,10,12(26),16,21,23-十烯 |
FLT; JAK; CDK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) 是一种有效的 CDK2/JAK2/FLT3 抑制剂(IC50:13/73/56 nM)。 | |||
T70895 |
H 35-25
|
||
H 35-25 is a beta 2-antagonist. | |||
T62056 | (E/Z)-Zotiraciclib hydrochloride | ||
(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride 是有效的 CDK2,JAK2和 FLT3抑制剂。(E/Z)-Zotiraciclib 可用于癌症研究。 | |||
T63998 | (E/Z)-Zotiraciclib citrate | ||
(E/Z)-Zotiraciclib ((E/Z)-TG02) citrate 是CDK2、JAK2 和 FLT3 的有效抑制剂,能够用于研究癌症。 | |||
T70897 | Zotiraciclib HCl | ||
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, w... |